Protein Tyrosine Kinase
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 24010 | Zasocitinib | 2272904-53-5 | ≧98.0% |  |
| Zasocitinib is under development for the treatment of moderate to severe plaque psori | ||||
| 24011 | Zongertinib | 2728667-27-2 | ≧98.0% |  |
| Zongertinib [BI 1810631] is a human epidermal growth factor receptor 2 (HER2) inhibit | ||||
| 24025 | BIIB-129 | 2770960-52-4 | ≧98.0% |  |
| BIIB129 is a covalent, selective, small molecule inhibitor of Bruton's tyrosine k | ||||
| 24073 | Dabogratinib ( TYRA-300 ) | 2800223-30-5 | ≧98.0% |  |
| Dabogratinib ( TYRA-300 ) is an Oral Selective FGFR3 Inhibitor (IC50 = 11 nM) for the | ||||
| 25052 | Lazertinib mesylate | 2247995-37-3 | ≧98.0% |  |
| Lazertinib is a an orally available third-generation, selective inhibitor of certain | ||||
| 25089 | Irpagratinib | 2230974-62-4 | ≧98.0% |  |
| Irpagratinib is an orally bioavailable, selective inhibitor of human fibroblast growt | ||||
| 25091 | Rilzabrutinib ( PRN1008 ) | 1575591-66-0 | ≧98.0% | _1575591-66-0.png) |
| Rilzabrutinib ( PRN1008 ) is an oral, reversible, covalent, small-molecule inhibitor | ||||
| 25166 | Vepafestinib ( Synonyms: TAS0953 ; HM06) | 2129515-96-2 | ≧98.0% | _2129515-96-2.png) |
| Vepafestinib, also known as HM06 and TAS0953, is a RET-selective inhibitor with enhan | ||||
| 25192 | CBR-470-1 | 2416095-06-0 | ≧98.0% |  |
| CBR-470-1 is an Inhibitor of the glycolytic enzyme PGK1that induces Nrf2 activity. | ||||
| 25191 | Z57346765 | 1016340-64-9 | ≧98.0% |  |
| Z57346765 is a PGK1-specific inhibitor that reduces the activity of metabolic enzymes | ||||
| 25197 | Bexobrutideg ( NX-5948 ) | 2649400-34-8 | ≧98.0% | _2649400-34-8.png) |
| Bexobrutideg (NX-5948) is a BTK degrader. | ||||
| 25198 | Bezuclastinib | 1616385-51-3 | ≧98.0% |  |
| Bezuclastinib is an oral, small-molecule inhibitor of the kinase activity of the KIT | ||||